The mission of the Immunology Laboratory (IML) is to investigate novel aspects of the cellular immune response to pathogens in support of the rational development of a vaccine against HIV and other lethal human viral pathogens.
The goal of the Viral Pathogenesis Laboratory (VPL) is to better understand basic aspects of viral pathogenesis and apply that knowledge toward development of safer and more effective vaccines.
The mission of the Vaccine Research Center (VRC) is to translate basic scientific knowledge into vaccine products intended for clinical use. In order to carry out the development and analysis of new vaccine candidates, the VRC has established several laboratories, including the Virology Laboratory (VL).
The primary mission of the VRC Clinical Trials Program (CTP) is to carry out clinical research through both an intramural program based at the National Institutes of Health (NIH) Clinical Center and through a broad range of support for external trials conducted by VRC collaborators and partners.
The Vaccine Research Center (VRC) Regulatory Science and Strategy Program (RSSP) aims to advance and support the VRC mission to discover, develop, and evaluate novel vaccines and antibody-based products.
The Translational Research Program (TRP) serves three major functions at the VRC: 1) provides centralized support and service for all in vivo research conducted at the VRC, 2) conducts collaborative research and animal model development, and 3) operates a fully accredited lab animal facility.
The goal of the Vaccine Immunology Program (VIP) is to facilitate the coordinated development and deployment of state-of-the-art technologies and analyses, which can be utilized effectively for vaccine discovery, early development and testing of clinical products.
The goal of the Vaccine Production Program Laboratory (VPPL) is to efficiently translate candidate research vaccines into materials for proof-of-concept clinical trials and to enable advanced development and licensure by partners.